Tumor Lysis SyndromeDefinition Simultaneous death of many cancer cells produces release to blood of enormous quantities of products of their destruction. | When? May particularly occur during initial phase of treatment of pts. w/ large chemosensitive tumors | Symptoms Hyperphosphatemia
Hyperuricemia
Hyperkalemia (life-threatening: cardiac arrhytmias)
Hypocalcemia secondary to formation of calcium phosphate: tetany, mental agitation, seizures
Acute renal failure | Diagnosis Based on development of
-increased lvl. of serum uric acid (8mg%) , phosphate (4,5 mg%) , and potassium (6mg%)
-decreased levels of serum calcium (7mg%)
-increased serum creatinine (1,5 x upper normal limit)
-cardiac arrhythmias or death, seizures | Management: • Forced diuresis 3 L/m2 PWE + furosemide
• Allopurinol to fight hyperuricemia (protein degradation).
• Novel agent: rasburicase |
Hypercalcemia - Clinical SymptomsPts. w/ Ca. conc. b/w 10.5 & 12 mg/dl usually asymptomatic | Clinical manifestations appear w/ higher lvls. | Renal | polyuria
nephrolithiasis (chronic HC) | GI | anorexia
nausea
vomiting
constipation
pancreatitis | Neuro-psych | weakness
fatigue
confusion
stupor
coma | CV | shortened QT interval on ECG
bradyarrhythmias
heart block
cardiac arrest | Ocular | band keratopathy (chronic HC) |
| | Local RadiotherapyTeleradiotherapy tumor irradiated from a distant (usually ~ 1m) source | Brachytherapy irradiation source is placed @ direct vicinity of irradiated tissue
(aka. Curietherapy) |
BrachytherapyContact or intracavital irradiation Installation of radiation source into cavity or through a natural route | Interstitial irradiation Insertion of the radioactive source interstitially | LDR (low-dose-rate) Currently, most freq. = Cesium 137
--> dose rate: 1 cGy/min
Intracavital: most freq. cervical ca.
Interstitial: oral cavity ca. , pharyngeal ca. , prostate ca. , sarcoma | HDR (high-dose-rate) Currently, most freq. = Iridiuim 192
--> dose rate: 100 cGy/min
Intracavital: vaginal ca. , oesophageal ca. , lung ca. , sarcoma
Interstitial: prostate ca. |
TeleradiotherapyConventional orthovolt (125-500 kV)
-can only be used for palliative tx. of superficially located metastases
--> practically not used these days | Megavolt telecobaltotherapy, photons & electrons from linear accelerator, neutrons from either neutron generator or cyclotrone
--> energy: 4 - 20 MeV |
Renal Ca. - Clinical PresentationTypical Triad | hematuria
abd. pain
flank / abd. mass (palpable tumor) | Less freq. | fever
weight loss
anemia
varicocele (abn. enlargement of pampiniform venous plexus)
PARANEOPLASTIC SYNDROMES:
--> erythrocytosis
--> hypercalcemia
--> nonmetastatic hepatic dysfunc. (Stauffer's synd.)
--> acquired dysfibrinogenemia |
| | Pancreatic cancerNotes Freq. site = Head of pancreas
No screening test available
5-year survival < 5%
Median age of diag. = 72 y/o
Peak incidence - 65-84 y/o
Males > Females | Clinical Features Pain
Obstructive Jaundice
Weight loss
Anorexia | Risk Factors • Cigarette Smoking, Obesity, Non-hereditary Chronic Pancreatitis
• Environmental Factors (diet, coffee), prev. partial gastrectomy / cholecystectomy & H. pylori | Physical Findings` (+) Courvoisier’s sign
• Palpable, nontender gallbladder
(+) Virchow’s Node
Advanced Disease
• Abdominal Mass, Hepatomegaly, Splenomegaly, Ascitis | Diagnostic Procedures Ultrasound
CT Scan
ERCP
Endoscopic US
MRCP
FDG-PET* | CA 19-9 (Serum Marker) • 80-90% sensitivity & specificity
• Suggestive of diag. pancreatic ca.
• Prognostic impilcations – Very high levels w/ inoperable disease
• Serial evaluation useful for monitoring response to tx.
• Detecting recurrence in pts. w/ completely resected tumors | Treatment Symptom management
Endoscopic biliary / duodenal stenting
Intestinal bypass surgery
Deoxycytidine analogue Gemcitabine |
*Excluding occult distal metastasis BI-RADS0 (incomplete) | Recommend add. imaging --> mammogram / targeted US | 1 (negative) | Routine breast MR screening if cumulative lifetime risk ≥ 20% | 2 (benign) | Routine breast MR screening if cumulative lifetime risk ≥ 20% | 3 (prob. benign) | Short-interval (6 mth) follow-up | 4 (suspicious) | Tissue diagnosis | 5 (highly suggestive of malignancy) | Tissue diagnosis | 6 (known biopsy-proven malignancy) | Surgical excision when clinically appropriate |
Breast Imaging Reporting and Database System score.
- Scoring syst. used by radiologists describe mammogram results
- Most efficient tool to help detect breast cancer, esp. at its earliest stage
*Table taken from UCSF Department of Radiology & Biomed. Imaging |
Created By
Metadata
Comments
No comments yet. Add yours below!
Add a Comment
Related Cheat Sheets
More Cheat Sheets by NKeeveepuff